Terminated PHASE3 INTERVENTIONAL 3-arm NCT01931566

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW)

A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects

Sponsor: Takeda

Conditions Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions Pioglitazone Pioglitazone placebo

Updated 10 times since 2017 Last updated: Aug 29, 2019 Started: Aug 1, 2013 Primary completion: Jul 24, 2018 Completion: Sep 6, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of efficacy of the drug; no safety concern

Other terminated trials from Takeda

See all terminations from Takeda

Other Mild Cognitive Impairment Due to Alzheimer's Disease trials with similar outcome

NCT02284906 · Phase PHASE3 · May 2018

Browse all Mild Cognitive Impairment Due to Alzheimer's Disease trials

A PHASE3 clinical study on Mild Cognitive Impairment Due to Alzheimer's Disease, this trial is terminated or withdrawn. The trial is conducted by Takeda and has accumulated 10 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Oct 2019 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Sep 2019 — Oct 2019 [monthly]

Terminated PHASE3
Sep 2018 — Sep 2019 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda
Zinfandel Pharmaceuticals Inc.

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Atlanta, United States , Basel, Switzerland , Berlin, Germany , Blackpool, United Kingdom , Bristol, United Kingdom , Charleston, United States , Chicago, United States , Concord, United States , Cordova, United States and 45 more locations